Elixir Medical Corporation

Print Article

PRESS RELEASE

Elixir Medical Corporation to Announce New Clinical Data on Fully Bioresorbable Drug Eluting Coronary Scaffold System and Drug Eluting Stent System at EuroPCR

Sunnyvale, CAMay 8, 2012—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will release six-month clinical data for its fully bioresorbable drug-eluting scaffold system, the DESolve™ Bioresorbable Coronary Scaffold, at the EuroPCR Hot Line session in Paris on Wednesday, May 16.

The DESolve I Clinical Study was a non-randomized trial to study the safety and performance of the DESolve™ Bioresorbable Coronary System in patients with single, de novo coronary artery blockages and followed up by QCA (Quantitative Coronary Angiography), IVUS (Intravascular Ultrasound), OCT (Optical Coherence Tomography), MSCT (Multi Slice Computed Tomography) and clinical endpoints at 6 months. The DESolve scaffold, made from a proprietary poly-L Lactic Acid (PLLA)-based polymer, provides mechanical support to the artery while delivering an anti-proliferative drug, and is designed to bioresorb in the body within 1-2 years.  Fifteen patients were enrolled in Europe and New Zealand.

Elixir will also announce new data on its other drug eluting stent platforms during the conference.  Following are the details of Elixir Medical’s programs and activities at the EuroPCR conference in Central European Summer Time (CEST):

Tuesday, May 15: 16:09 – 16:18 (4:09 – 4:18 PM), Room 342B

Session: Comparison of outcomes between DES (Part 1)

EXCELLA BD Study: 12-month clinical and 6-month QCA and IVUS results.

Multi-center, prospective, randomized, single blind evaluation of a Novolimus-eluting stent with bioabsorbable polymer compared to Zotarolimus-eluting stent.

 

Tuesday, May 15: 19:00 – 20:00 (7 – 8 PM), Le Meridien Hotel, Degas Room

Elixir Medical Cocktail Reception with Program Update

Space is limited: Please register in advance at parisevent@elixirmedical.com

 

Wednesday, May 16: 10:40 – 10:52, Room 252AB

Session: First-in-man trials and novel clinical applications, Hot Line

DESolve: A Myolimus-eluting bioresorbable coronary scaffold first-in-man trial. First report imaging and clinical data to be presented as a late-breaking session.

 

Thursday, May 17:  15:15 – 15:25 (3:15 – 3:25 PM), Room Maillot

Session: Glimpse into the Future, New Devices

Emerging bioresorbable scaffolds: a report from the PCR Focus Group on Elixir Technology

 

Friday, May 18:  12:09 – 12:18, Room 342B

Session: Clinical evaluation of bioresorbable vascular scaffolds

Multi-centre, first-in-man evaluation of the Myolimus-eluting bioresorbable coronary scaffold: 6-month clinical and imaging results

 

Elixir Medical will have a booth at EuroPCR:  Booth # F5, Level 1, Hall Passy. The booth will be open Tues., May 15 through Fri., May 18.

About Novolimus and Myolimus

Novolimus and Myolimus belong to the powerful macrocyclic lactone class of drugs. This family of drugs is the most widely used for drug eluting stent applications. Novolimus, a metabolite of sirolimus, was developed internally by Elixir for use in site- specific therapies and has an established safety and efficacy profiles. Myolimus is a Novartis Pharma AG compound.  Elixir has a license to Myolimus.

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com

 

***

 

Contact: Vinayak Bhat, PhD   

Ph: (408) 636-2000